Dashboard
1
High Management Efficiency with a high ROE of 10.82%
2
Company has very low debt and has enough cash to service the debt requirements
3
The company has declared Negative results for the last 3 consecutive quarters
4
With ROE of 5.82%, it has a very attractive valuation with a 1.54 Price to Book Value
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
6
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 197,019 Million (Small Cap)
26.00
NA
0.00%
-0.23
5.30%
1.68
Revenue and Profits:
Net Sales:
20,647 Million
(Quarterly Results - Jun 2025)
Net Profit:
3,070 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.29%
0%
-5.29%
6 Months
4.91%
0%
4.91%
1 Year
-15.54%
0%
-15.54%
2 Years
-14.19%
0%
-14.19%
3 Years
-28.4%
0%
-28.4%
4 Years
-12.53%
0%
-12.53%
5 Years
-8.09%
0%
-8.09%
Nakanishi, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.58%
EBIT Growth (5y)
10.12%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.52
Tax Ratio
49.70%
Dividend Payout Ratio
51.30%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
23.45%
ROE (avg)
10.82%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.54
EV to EBIT
10.97
EV to EBITDA
7.68
EV to Capital Employed
1.69
EV to Sales
1.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.41%
ROE (Latest)
5.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
20,647.20
18,542.50
11.35%
Operating Profit (PBDIT) excl Other Income
5,635.00
4,755.30
18.50%
Interest
40.00
35.80
11.73%
Exceptional Items
-25.50
0.00
Consolidate Net Profit
3,070.00
440.40
597.09%
Operating Profit Margin (Excl OI)
204.60%
181.30%
2.33%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 11.35% vs -9.19% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 597.09% vs -11.64% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
77,041.40
59,692.40
29.06%
Operating Profit (PBDIT) excl Other Income
20,460.40
17,711.50
15.52%
Interest
67.30
13.30
406.02%
Exceptional Items
-3,464.50
11,509.10
-130.10%
Consolidate Net Profit
8,578.80
22,802.60
-62.38%
Operating Profit Margin (Excl OI)
189.50%
238.20%
-4.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 29.06% vs 22.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -62.38% vs 82.81% in Dec 2023
About Nakanishi, Inc. 
Nakanishi, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






